Santhera Initiates Collaboration with the European Vision Institute Clinical Research Network in LHON
(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera Initiates Collaboration with the European Vision Institute Clinical
Research Network in LHON
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Liestal, Switzerland, July 11, 2013 - Santhera Pharmaceuticals (SIX: SANN)
announced today that it has initiated a collaboration with the European Vision
Institute Clinical Research Network (EVICR.net) to assess the natural course of
Leber's Hereditary Optic Neuropathy (LHON). Data from this collaboration is
intended to be included in a marketing authorization application (MAA) for
Raxone(®) (idebenone) in Europe.
Under the collaboration, Santhera will receive data on the change in vision over
time in untreated LHON patients from selected EVICR.net centers. This data will
be compared to the vision outcomes data currently being collected from
physicians around the world who are treating LHON patients with Raxone(®) in
clinical practice.
"Lack of natural history data is a general shortcoming in clinical research of
rare diseases and a limitation in the development of orphan drugs", commented
Thomas Meier, CEO of Santhera. "We have initiated this collaboration with
EVICR.net to increase our understanding of changes in vision in LHON patients,
including spontaneous recovery after severe vision loss. We expect to integrate
these data as a comparator group in a revised MAA for Raxone(®) in the treatment
of LHON that we plan to submit as early as the first quarter next year."
"We are excited about this collaboration and the opportunity to support Santhera
in the collection of natural history data", added José-Alain Sahel, Professor at
the Université Pierre et Marie Curie, Director of the Institut de la Vision,
Chairman at the Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
(Paris, France) and Chairman of EVICR.net. "EVICR.net was established as
European consortium to promote academic translational research and support
industry in conducting clinical research, including assessment of natural
history data, which is of particular relevance in rare diseases such as LHON."
About EVICR.net
European Vision Institute Clinical Research Network (EVICR.net) was established
in 2010 as an independent European Economic Interest Grouping to serve as a
platform for clinical trial research in ophthalmology in Europe. It is a network
of 76 European ophthalmological clinical research sites in 16 European countries
dedicated to perform clinical research in ophthalmology with the highest
standards of quality, following the European and international directives for
clinical research according to harmonized standard operating procedures.
About LHON
Leber's Hereditary Optic Neuropathy (LHON) is a heritable genetic disease
causing blindness. The disease typically presents in young adults, mostly men,
as rapid, painless loss of central vision in one eye, followed by visual loss in
the fellow eye within a few months of the onset of symptoms, leading to
blindness. Over 95% of patients harbor one of three pathogenic mutations of the
mitochondrial DNA which cause a defect in the complex I subunit of the
mitochondrial respiratory chain. This defect leads to decreased cellular energy
(ATP) production, increased oxidative stress and retinal ganglion dysfunction
which cause progressive loss of visual acuity and blindness.
Santhera develops Raxone(®) (idebenone) as treatment for patients with LHON. The
synthetic short-chain benzoquinone and a cofactor for the enzyme NAD(P)H:quinone
oxidoreductase (NQO1) is capable of transferring electrons directly onto complex
III of the mitochondrial electron transport chain, thereby circumventing the
complex I defect and restoring cellular energy levels in retinal ganglion cells
and promoting recovery of visual acuity.
* * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan mitochondrial and neuromuscular diseases,
areas of high unmet medical need with no current therapies. For further
information, please visit www.santhera.com.
Raxone(®) is a trademark of Santhera Pharmaceuticals.
For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier(at)santhera.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
News release EVICR.net:
http://hugin.info/137261/R/1715593/570139.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1715593]
Unternehmensinformation / Kurzprofil:
Datum: 11.07.2013 - 07:15 Uhr
Sprache: Deutsch
News-ID 277382
Anzahl Zeichen: 6563
contact information:
Town:
Liestal
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 240 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Santhera Initiates Collaboration with the European Vision Institute Clinical Research Network in LHON"
steht unter der journalistisch-redaktionellen Verantwortung von
Santhera Pharmaceuticals Holding AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
